bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 15.47M |
| Revenue (ttm) | 9.37M |
| Net Income (ttm) | -8.45M |
| Shares Out | 15.58M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 476,156 |
| Open | 1.240 |
| Previous Close | 1.180 |
| Day's Range | 0.982 - 1.290 |
| 52-Week Range | 0.831 - 3.620 |
| Beta | 2.87 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+504.35%) |
| Earnings Date | Nov 14, 2024 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas. [Read more]
Financial Performance
In 2023, bioAffinity Technologies's revenue was $2.53 million, an increase of 52627.44% compared to the previous year's $4,803. Losses were -$7.94 million, -2.66% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BIAF stock is "Strong Buy" and the 12-month stock price forecast is $6.0.
News
Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies President and CEO Maria Zannes will be featured on RedChip Companies' investor webinar on Thursday, Dec. 19.
bioAffinity Technologies Set for Continued Expansion in 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity reports successful execution of its pilot marketing program and steady growth in sales of the CyPath® Lung test in 2024.
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies releases financial results for the three months ended September 30, 2024.
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development.
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies receives a Japanese patent for the method behind the CyPath® Lung diagnostic test for early-stage lung cancer.
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In...
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement.
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
JERSEY CITY, N.J. , Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that– bioAffinity Technologies, I...
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement.
bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique biological samples like sputum used in CyPath® Lung.
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies names J. Michael Edwards as Chief Financial Officer.
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at risk for lung cancer.
Peer-Reviewed Study: bioAffinity Technologies' CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--Study demonstrates how CyPath Lung diagnostic test for lung cancer can significantly reduce healthcare costs for both public and private insurers.
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--J. Michael Edwards replaces Michael Dougherty as bioAffinity CFO; Dougherty is leaving for a position in the energy sector in the Pacific Northwest.
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports financial results and operational highlights for the quarter ended June 30, 2024.
WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
JERSEY CITY, N.J. , Aug. 5, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that in connection with the BioAff...
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of registered direct offering, private placement and warrant inducement for gross proceeds of $1.75 million.
WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
JERSEY CITY, N.J. , Aug. 2, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc...
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of registered direct offering and concurrent private placement and warrant inducement.
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big M...
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies raises the 2024 full-year forecast for sales of CyPath Lung, a noninvasive test for lung cancer, by 85%.
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™...
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a 139% growth in the number of pulmonology practices and physicians ordering CyPath Lung for their patients.
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technology reports record Q1 2024 revenue driven by accelerating sales of lung cancer diagnostic CyPath Lung.
bioAffinity Technologies News Update
SAN ANTONIO--(BUSINESS WIRE)-- #ATS--bioAffinity reports ramp in sales of CyPath® Lung, expanded sales team, new Patient Coach and upcoming presentation at American Thoracic Society.